CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

Journal of Clinical Psychopharmacology

Volumn 19, Issue 2, 1999, Pages 155-163

  Alfaro, Cara L ^a,e   Lam, Y W Francis ^a,c   Simpson, Joseph ^d   Ereshefsky, Larry ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d Alamo Mental Health Group   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DESIPRAMINE; DEXTROMETHORPHAN; DEXTRORPHAN; FLUOXETINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DEPRESSION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INHIBITION KINETICS; INSOMNIA; MALE; PANIC; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; VERTIGO;

ADULT; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; PAROXETINE; REFERENCE VALUES; SERTRALINE;

EID: 0032962216     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199904000-00011     Document Type: Article

References (36)

1. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-9.
2. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11:930-57.
3. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific second-generation antidepressant. Pharmacotherapy 1987;7:1-14.
4. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15:84S-99S.
5. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32[suppl 1]:1-21.
6. Ereshefsky L, Alfaro CL, Lam YWF. Treating depression: potential drug interactions. Psych Annals 1997;27:244-58.
7. Goodnick PJ. Influence of fluoxetine on plasma levels of desipramine [letter]. Am J Psychiatry 1989;146:552.
8. Downs JM, Downs AD, Rosenthal TL, Deal N, Akiskal HS. Increased plasma tricyclic antidepressant concentrations in two patients currently treated with fluoxetine. J Clin Psychiatry 1989; 50:226-7.
9. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
10. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
11. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
12. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
13. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
14. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56.
15. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
16. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388-9.
17. Spina E, Birgerson C, von Bahr C, Ericsson O, Mellstrom B, Steiner E, Sjoqvist F. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-82.
18. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
19. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
20. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15: 243-6.
21. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44:349-55.
22. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-6.
23. Lam YW, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993:300-4.
24. Riesenman C, Lam YWF, Ereshefsky L. Intraindividual variability of the dextromethorphan/dextrorphan ratio in extensive metabolizers [abstract]. Clin Pharmacol Ther 1996;59:137.
25. Idle JR. Poor metabolisers of debrisoquine reveal their true colours [letter]. Lancet 1989;2:1097.
26. Yue QY, Bertilsson L, Dahl-Puustinen, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese [letter]. Lancet 1989;2:870.
27. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach RK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-6.
28. Beasley CM, Bosomworth JC, Wernicke JF. Fluoxetine relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
29. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-9.
30. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder a double-blind controlled study. J Clin Psychopharmacol 1997;17:4-10.
31. Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16:373-8.
32. Decker J, Lindley C, Williamson K, McCune J, Graff D, Carson S, Pieper J. Gender differences and intrasubject variability in CYP2D6 activity in extensive metabolizers of dextromethorphan [abstract]. Clin Pharmacol Ther 1998;63:215.
33. Butler MA, Lang NP, Young JF, Caporaso NE, Vinels P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-27.
34. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
35. Bock KW, Schrenk D, Forster A, Griese E-U, Mörike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
36. 1-receptor occupancy. Clin Pharmacol Ther 1995;58:210-20.